Every 424B that bioAffinity Technologies, Inc. Warrant (BIAFW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BIAFW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAFW filings page.
bioAffinity Technologies (BIAF) is offering 116,545 common shares and up to 536,836 pre-funded warrants; the supplement also registers 536,836 underlying shares. Each pre-funded warrant sold reduces common shares offered one-for-one. The share price is $6.122; each pre-funded warrant costs $6.115 and has a $0.007 exercise price. They are immediately exercisable, subject to a 4.99% beneficial-ownership limit or 9.99% at a holder’s election.
The company intends net proceeds for working capital and general corporate purposes, including laboratory test and therapeutic product development, general and administrative matters, and capital expenditures. It states immediate net tangible book value dilution to common-share purchasers of $1.32 per share. Separately, it is selling up to 980,072 unregistered warrants in a concurrent private placement, exercisable at $6.122 per share beginning on stockholder approval and for five years thereafter. Audited statements for the years ended December 31, 2025 and December 31, 2024 include an explanatory paragraph citing conditions that raise substantial doubt about the company’s ability to continue as a going concern.
bioAffinity Technologies, Inc. (BIAF) reduced to $0 the dollar amount of common stock it may sell under its at-the-market agreement with WallachBeth Capital LLC. From and after October 8, 2026, it may not offer or sell shares under that agreement; it may file a further supplement to increase the amount if its capacity under General Instruction I.B.6 of Form S-3 increases. During the prior twelve-calendar-month period ending on and including the supplement date, the company offered and sold $1,800,000 of common stock under that instruction. While non-affiliate market value is less than $75,000,000, sales under the instruction are limited to one-third of aggregate market value in any 12-month period; reported non-affiliate market value was approximately $17,707,550 as of October 8, 2026.
bioAffinity Technologies, Inc. is registering up to 1,692,408 shares of Common Stock for resale by a selling stockholder, all issuable upon exercise of pre-funded, Series A and Series B warrants from an August 2026 private placement. The company will not receive proceeds from these resales.
If all 1,692,408 underlying warrants are exercised for cash, the company would receive approximately $5.7 million in gross proceeds. Shares outstanding were 600,736 as of September 2, 2026, and would be 2,293,144 if all warrant shares are issued; this is a baseline figure, not the amount being offered for sale.
bioAffinity develops noninvasive lung diagnostics, led by its CyPath® Lung test, and is expanding distribution through a new agreement with AvMEDICAL targeting U.S. government healthcare systems. A 1-for-15 reverse stock split became effective on August 21, 2026. The company reported net losses of $14.9 million in 2025 and $3.4 million in the quarter ended June 30, 2026, and its auditor has included a going-concern explanatory paragraph.